Novant adds URO-1 to vendor list, begins enrollment in trial
URO-1, a Greensboro medical device company in prostate and soft tissue cancer diagnostics, said it was recently approved by Novant Health as a designated vendor for URO-1’s SUREcore and coreCARE platform.
URO-1’s biopsy system consists of the SUREcore set of instruments, designed to provide a bigger volume of prostate tissue with higher quality than standard biopsy instruments, and the coreCARE specimen retrieval kit. Both are cleared for all soft tissue biopsies by the U.S. Food and Drug Administration.
The company also said that it has initiated patient enrollment in its multi-center, prospective and randomized control study of SUREcore and coreCARE. The centers conducting the study are comprehensive cancer centers designated by the National Cancer Institute.
The North Carolina Biotechnology Center provided a $250,000 Small Business Research Loan to URO-1 in 2018.